Holen Sie sich die Stockscreener-App
0.6463
0.83%
0.0053
Handel nachbörslich:
.65
0.0037
+0.57%
Schlusskurs vom Vortag:
$0.641
Offen:
$0.725
24-Stunden-Volumen:
69,449
Relative Volume:
1.78
Marktkapitalisierung:
$28.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.25M
KGV:
-1.8293
EPS:
-0.3533
Netto-Cashflow:
$-8.02M
1W Leistung:
-8.34%
1M Leistung:
-8.20%
6M Leistung:
-40.71%
1J Leistung:
-40.16%
1-Tages-Spanne:
$0.585
$0.7375
1-Wochen-Bereich:
$0.585
$0.7439
52-Wochen-Spanne:
$0.585
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Firmenname
Estrella Immunopharma Inc
Sektor
Branche
Telefon
(510) 318-9098
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.6463 | 32.41M | 0 | -13.25M | -8.02M | -0.3533 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Estrella Immunopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half - GuruFocus
Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - Kalkine
Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center StageLong Short Pair - vinanet.vn
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma (ESLA) Holds at $0.72 as Support Firms in Quiet Micro-Cap SessionIchimoku TK Cross - vinanet.vn
ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignInstitutional Buy Signals - vinanet.vn
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatSystematic Flow - vinanet.vn
Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan
Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary - TradingView
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella adds fourth site to EB103 lymphoma trial - Investing.com
Estrella Immunopharma Inc (ESLA) Stock News Today - TradingKey
Estrella Immunopharma (ESLA) Stock Price, News & Analysis - MarketBeat
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Estrella Immunopharma (ESLA) Rallies 6.11% as CAR T-Cell Focus Draws Investor AttentionTotal Put Call - dars.gov.et
Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - tradingview.com
Estrella adds third site to EB103 lymphoma trial - Investing.com
Estrella adds third site to EB103 lymphoma trial By Investing.com - Investing.com South Africa
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Estrella Immunopharma (ESLA) Holds at $0.71 as Downside Pressures Remain ContainedTRIN Signal - dars.gov.et
Price to sales forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella activates second site for EB103 lymphoma trial By Investing.com - Investing.com Canada
Estrella activates second site for EB103 lymphoma trial - Investing.com
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Balance Sheet - TradingKey
Estrella Immunopharma Inc (ESLA) Cash Flow - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.750|Chg%:-0.030 - TradingKey
TradingKey - TradingKey
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.780| - TradingKey
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Estrella doses first patient in EB103 trial expansion phase - Investing.com
Estrella doses first patient in EB103 trial expansion phase By Investing.com - Investing.com Canada
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma, Inc. (ESLA) stock price, news, quote and history - Yahoo Finance UK
Estrella Immunopharma Inc. (ESLA) Q2 2026 Earnings: Wider-than-Expected Loss Despite Double-Digit Stock Rally - vinanet.vn
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma Warrants (ESLAW) Slide 7.5% as Support and Resistance Converge at $0.08Ichimoku Kumo Twist - vinanet.vn
Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):